{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-22-000004","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.359291+00:00","generated_at":"2026-06-27T20:26:28.000425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neurocrine Biosciences reports preliminary Q4 2021 INGREZZA sales ~$301M, FY ~$1.1B","bullets":["Q4 INGREZZA net sales ~$301M ($296M inventory-adjusted), up 25% YoY; prescriptions up 32% YoY.","Full-year 2021 INGREZZA net sales ~$1.1B.","Full-year 2022 INGREZZA sales guidance to be provided on Feb 11, 2022 earnings call.","Pipeline: sNDA for valbenazine in Huntington chorea in 2H 2022; Phase 2 data for NBI-827104 mid-2022.","Company now has 13 mid-to-late-stage clinical programs with data readouts over the next two years."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-22-000004","json":"https://secwatch.observer/filing/0000914475-22-000004.json","markdown":"https://secwatch.observer/filing/0000914475-22-000004.md","text":"https://secwatch.observer/filing/0000914475-22-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000004/0000914475-22-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000004/nbix-20220106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:26:28.000425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}